Tempus AI launches 100,000 whole-genome dataset for AI-driven healthcare research

Tempus AI Builds Research Platform for AI-Driven Healthcare Innovation

Tempus AI has announced an ambitious initiative to create a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years1

1

2

2

. This represents a significant step forward in precision medicine, as the company works to bridge the gap between genomic data and practical clinical applications. The effort will create the first de-identified multimodal whole-genome sequencing dataset built specifically around disease populations and patient outcomes, optimized for AI-driven research. Once complete, Tempus AI plans to expand the initiative with a goal of reaching one million genomes1

1

.

Why This Whole-Genome Dataset Matters for AI Researchers

Existing population-scale genome programs are largely drawn from general populations and are not designed to link genomic data with longitudinal disease and treatment outcomes1

1

. Tempus AI is addressing this gap by building infrastructure that connects diagnostics, multimodal clinical data, and AI at scale. Eric Lefkofsky, Founder and CEO of Tempus, emphasized that "a large dataset is only valuable if you can turn it into insight"1

1

. The company has spent the last decade developing the necessary infrastructure to make this vision a reality. Tempus AI operates one of the largest multimodal real-world oncology databases and has already used it to enhance hundreds of drug development decisions2

2

.

Integration with Tempus Lens and Multimodal Data Environment

The new whole-genome dataset will be integrated into Tempus AI's existing de-identified multimodal data environment, where researchers can access genomic information alongside clinical histories, imaging, pathology, and patient outcomes1

1

2

2

. Through Tempus Lens, researchers and model developers will be able to analyze data and build and validate AI models without moving datasets between systems. This seamless integration is designed to create a model-ready environment for AI researchers, enabling them to better understand disease progression and develop new AI-enabled insights for personalized patient care2

2

.

Building Foundation Models and Supporting AI-Enabled Healthcare Solutions

Tempus AI has spent years structuring data specifically for AI-derived insights, building its own oncology foundation models and supporting model development for other leading AI innovators2

2

. The company is now expanding beyond targeted gene panels into next-generation sequencing diagnostics to create a deeper understanding of the role the genome plays in disease progression and treatment response. Unlike datasets designed primarily for traditional analysis, this resource is built specifically to pair whole-genome data with longitudinal clinical information and a computational system for pre-training and post-training workflows2

2

. This approach enables therapeutic optimization and supports the development of clinical decision support tools that can improve patient outcomes.

Early Adopter Program and Timeline for General Availability

Development of the research platform is already underway, and the initial dataset is available through Tempus AI's Early Adopter Program1

1

2

2

. The company will onboard additional members in waves as the dataset grows, with general availability planned for mid-20271

1

. This phased rollout allows Tempus AI to refine the platform while providing early access to select researchers who can begin exploring the data immediately. Watch for how this platform influences drug development timelines and whether competing firms develop similar multimodal approaches to genomic data integration. The success of this initiative could reshape how AI researchers approach disease modeling and accelerate the development of algorithmic diagnostics and molecular pathology testing applications.